clinical trial · NCT04255433
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly and Company·phase3·completed·n = 13,299
Type 2 Diabetes MellitusTirzepatideDulaglutide
brief summary
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
started
May 29, 2020
primary completion
Jun 12, 2025
completion
Jun 12, 2025
last updated
Aug 24, 2025
official title
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol